Strength in numbers: AstraZeneca is making available preclinical data from more than 50 of its medicines to help accelerate the hunt for synergistic tumour-fighting drug combinations.
LONDON: Drugmaker AstraZeneca is harnessing the wisdom of crowds to help mix tomorrow's cancer drug cocktails.
The company said its decision to release preclinical data from more than 50 of its medicines was unprecedented in scale and would help accelerate the hunt for synergistic tumour-fighting drug combinations.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
